Harrow (NASDAQ:HROW) CFO Andrew Boll Purchases 3,500 Shares

Harrow, Inc. (NASDAQ:HROW) CFO Andrew Boll purchased 3,500 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was acquired at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the purchase, the chief financial officer owned 814,679 shares in the company, valued at $24,358,902.10. This trade represents a 0.43% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Harrow Trading Up 1.1%

HROW stock opened at $31.21 on Friday. Harrow, Inc. has a one year low of $25.21 and a one year high of $54.85. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -76.12 and a beta of 0.34. The company has a fifty day moving average price of $36.51 and a two-hundred day moving average price of $42.13. The company has a debt-to-equity ratio of 10.30, a current ratio of 2.48 and a quick ratio of 2.06.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The company had revenue of $44.20 million during the quarter, compared to the consensus estimate of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same period in the previous year, the company earned ($0.38) earnings per share. Equities analysts anticipate that Harrow, Inc. will post 0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HROW. Nomura downgraded shares of Harrow to a “neutral” rating in a research report on Wednesday, March 18th. Wall Street Zen lowered Harrow from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Harrow in a report on Thursday, March 19th. Cantor Fitzgerald reduced their price target on Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, Weiss Ratings lowered Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Harrow presently has a consensus rating of “Moderate Buy” and an average price target of $69.43.

Institutional Investors Weigh In On Harrow

A number of large investors have recently added to or reduced their stakes in HROW. Larson Financial Group LLC raised its holdings in Harrow by 13.1% in the 4th quarter. Larson Financial Group LLC now owns 2,446 shares of the company’s stock valued at $120,000 after acquiring an additional 284 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Harrow by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after purchasing an additional 341 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Harrow by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after purchasing an additional 369 shares during the period. Captrust Financial Advisors increased its position in shares of Harrow by 0.5% in the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock worth $3,428,000 after purchasing an additional 376 shares during the period. Finally, Alliancebernstein L.P. raised its stake in Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock valued at $1,422,000 after purchasing an additional 500 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.